Aprea Therapeutics, Inc. (APRE) stock
APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.46+0.01 (+2.60%)
Close on Nov 18, 2026Market cap $5.85MP/E –Yield –
Aprea Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aprea Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.17M. For fiscal 2025 it was -$12.89M. The highest annual figure on record is -$12.18M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.89M | – |
| FY2024 | Dec 31, 2024 | -$13.56M | – |
| FY2023 | Dec 31, 2023 | -$12.18M | – |
| FY2022 | Dec 31, 2022 | -$25.01M | – |
| FY2021 | Dec 31, 2021 | -$37.69M | – |
| FY2020 | Dec 31, 2020 | -$41.80M | – |
| FY2019 | Dec 31, 2019 | -$26.71M | – |
| FY2018 | Dec 31, 2018 | -$15.25M | – |
| FY2017 | Dec 31, 2017 | -$14.00M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.28M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.94M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.74M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.98M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.54M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.74M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.79M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.85M | – |
See a number that looks wrong?